Looking for biomarkers to help diagnose ankylosing spondylitis, rheumatoid arthritis and lupus earlier
Studies biomarkers to help diagnose ankylosing spondylitis, rheumatoid arthritis and lupus in adults.
Key facts
- Who runs it
- Universidade Nova de Lisboa
- Where
- Lisbon, PortugalSee the site
- Trial code
- Registry title
- Biomarkers in Inflammatory Rheumatic Diseases Diagnosis
- Status
- Recruiting
- People taking part
- 134 people, planned
- Started
- 31 Jan 2023
- Planned end
- 30 Jun 2025
- Type of study
- Observational, 4 groups
- Record updated
- 20 January 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with ankylosing spondylitis, rheumatoid arthritis or systemic lupus erythematosus who are otherwise in good health. Healthy controls of the same sex and age also take part.
- Age
- 18 to 65 years
- Sex
- Women and men
- Disease stage
- A diagnosis of ankylosing spondylitis, rheumatoid arthritis or systemic lupus erythematosus, made by the trial's stated criteria.
- Earlier treatment
- No earlier biologic therapy. Doses of pain medicines, oral corticosteroids and some disease drugs (MTX, leflunomide, SSZ, hydroxychloroquine) must be stable for 14 to 28 days before screening.
Main reasons for not taking part
- Current pregnancy or breastfeeding
- Any earlier biologic therapy
- Another type of inflammatory arthritis, or arthritis starting before age 17
- Any past cancer, or an uncontrolled medical condition
- Positive test for hepatitis B, hepatitis C or HIV
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Diagnosis of AS, RA, SLE according the mentioned criteria
- Ability to provide informed consent
- If entering the study on NSAIDs, tramadol, combination of paracetamol and codeine or hydrocodone, and/or non-opioid analgesics, subject must be on stable dose(s) for at least 14 days prior to the screening visit
- If entering the study on oral corticosteroids, subject must be on a stable dose of prednisone (≤ 10 mg/day), or oral corticosteroid equivalents, for at least 14 days prior to the screening visit
- If entering the study on MTX, leflunomide, SSZ, and/or hydroxychloroquine, subject must be on a stable dose of MTX (≤ 25 mg/week) and/or SSZ (≤ 3 g/day) and/or hydroxychloroquine (≤ 400 mg/day) or leflunomide (≤ 20 mg/day) for at least 28 days prior to the screening visit. A combination of up to two background csDMARDs is allowed
- Subject is judged to be in good health as determined by the Principal Investigator based upon the results of medical history, laboratory profile, physical examination, x-Ray performed at the Screening Visit
Who cannot take part
- Prior exposure to any biologic therapy
- Intra-articular joint or tendon sheaths injections, spinal/paraspinal injection(s), or parenteral administration of corticosteroids within 28 days prior to the Baseline Visit. Inhaled or topical corticosteroids are allowed
- Receipt of any live vaccine within 4 weeks prior to the screening visit
- Subject has a history of inflammatory arthritis of different etiology other than AS, RA or SLE (including but not limited to PsA, mixed connective tissue disease, reactive arthritis, scleroderma, polymyositis, dermatomyositis, fibromyalgia), or any arthritis with onset prior to 17 years of age
- Infections requiring hospitalization or intravenous treatment with antibiotics within 30 days or oral treatment with antibiotics within 14 days before enrollment
- History of clinically significant (per Investigator\'s judgment) drug or alcohol abuse within the last 6 months
- Any uncontrolled medical condition (e.g., uncontrolled diabetes mellitus, unstable ischemic heart disease)
- History of any malignancy
- Positive serology for hepatitis B, hepatitis C, or human immunodeficiency virus
- Note : Healthy Controls should be matched by gender and age. People with acute infections or injuries (in the last 6 months) or non-controlled chronic diseases (cardiac, metabolic, lung, neurologic, gastro-intestinal or renal) will be exclude. Family history of Auto-Immune diseases as diagnosed by a rheumatologist will be also excluded
- Current pregnancy or breastfeeding
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in Portugal
- ULS Lisboa Ocidental, Hospital de Egas MonizLisbon, PortugalContact: Fernando MP SantosTaking people
About the trial
What the trial wants to find out
Ankylosing spondylitis (AS), Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) are three diseases where early diagnosis remains a major challenge. However, early diagnosis is the main determinant for a better prognosis. In the early stage, symptoms may be nonspecific and often difficult to establish a differential diagnosis between rheumatic diseases and other diseases, namely infectious and cancer diseases.
The 4 groups in the trial
- Control
- Ankylosing Spondylitis
- Rheumatic Arthritis
- Systemic Lupus Erythematosus
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- BIRDD: Biomarkers in Inflammatory Rheumatic Diseases Diagnosis - Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus
- Plain-language title
- Looking for biomarkers to help diagnose ankylosing spondylitis, rheumatoid arthritis and lupus earlierGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06778343, who can take part
- Record updated
- 20 January 2025